Central Nervous System Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CNT005 MIFTS: 53	Central Nervous System Lymphoma Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Central Nervous System Lymphoma

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma ¹² ¹⁵ ¹⁷

Primary Central Nervous System Lymphoma ⁷¹

Primary Cns Lymphoma ¹²

Cns Lymphoma ⁷¹

Microglioma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Immune diseases Blood diseases Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3234

ICD9CM ³⁴ 200.5

NCIt ⁴⁹ C9301

SNOMED-CT ⁶⁷ 307649006

EFO ¹⁷ EFO_1000157

UMLS ⁷¹ C0280803 C0742472

Sources

Summaries for Central Nervous System Lymphoma

Disease Ontology : ¹² A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Teniposide and Fotemustine have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and b cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)

#	Related Disease	Score	Top Affiliating Genes
1	primary central nervous system lymphoma	34.8	PAX5 MYD88 MGMT CXCR5 CXCL13 BCL6
2	intraocular lymphoma	32.9	PAX5 IL10 CXCR5 CXCL12 BCL6
3	lymphoma, hodgkin, classic	31.4	PAX5 IL2 CD68 CCR6 BCL6
4	histiocytic sarcoma	31.1	CDKN2A CD68
5	uveitis	31.1	IL6 IL2 IL10 CXCR5
6	intravascular large b-cell lymphoma	31.0	MYD88 BCL6
7	follicular lymphoma	30.7	PAX5 MYC CXCR5 BCL6
8	acquired immunodeficiency syndrome	30.7	TP53 MYC IL6 IL2 IL10 CXCR5
9	primary mediastinal large b-cell lymphoma	30.7	CD274 BCL6
10	meningitis	30.7	IL6 IL2 IL10 CXCL13 CXCL12
11	graft-versus-host disease	30.7	IL6 IL2 IL10
12	demyelinating disease	30.6	IL6 IL2 IL10 CCR6
13	neurosyphilis	30.6	IL10 CXCR5 CXCL13
14	anaplastic oligodendroglioma	30.6	MGMT CDKN2A
15	spinal cord lymphoma	30.6	CCR6 BCL6
16	chorioretinitis	30.6	IL6 IL2 IL10
17	immune deficiency disease	30.6	IL6 IL2 IL10 CXCL12 CCR6 BCL6
18	glioblastoma multiforme	30.6	TP53 MYC MGMT IL6 IL2 CXCL12
19	lymphopenia	30.5	IL6 IL2 IL10 CCR6
20	viral encephalitis	30.5	IL6 IL10 CCR6
21	testicular lymphoma	30.5	MYD88 FOXP1 CD274 BCL6
22	posterior uveitis	30.5	IL6 IL2 CCR6
23	chickenpox	30.5	IL6 IL2 IL10 CCR6
24	lymphoplasmacytic lymphoma	30.5	PAX5 MYD88 CXCL12
25	monoclonal paraproteinemia	30.5	PRDM1 PAX5
26	oligodendroglioma	30.5	TP53 MGMT IL2 CDKN2A
27	lymphoblastic lymphoma	30.4	TP53 PAX5 MYC CDKN2A BCL6
28	t-cell adult acute lymphocytic leukemia	30.4	TP53 IL2 CCR6
29	brain stem glioma	30.4	TP53 MGMT CDKN2A
30	spinal cord disease	30.4	IL6 IL2 IL10 CCR6
31	plasmablastic lymphoma	30.3	PRDM1 MYC CDKN2A BCL6
32	orbit lymphoma	30.3	MALT1 FOXP1
33	plasma cell leukemia	30.3	MYC IL6 CDKN2A
34	relapsing-remitting multiple sclerosis	30.3	IL6 IL2 IL10 CCR6
35	panuveitis	30.3	IL6 IL10 CCR6
36	retinal detachment	30.3	TP53 IL6 IL10 CXCL12
37	aphthous stomatitis	30.3	IL6 IL2 IL10
38	t-cell/histiocyte rich large b cell lymphoma	30.3	CD68 BCL6
39	meningoencephalitis	30.3	IL6 IL10 CCR6
40	peripheral t-cell lymphoma	30.3	TP53 PAX5 IL2 CXCL13 CD274 BCL6
41	severe combined immunodeficiency	30.2	IL6 IL2 IL10 CXCL12 CCR6
42	bacterial infectious disease	30.2	MYD88 IL6 IL10 CCR6
43	meningioma, familial	30.2	TP53 MYC MGMT CDKN2A CD68
44	myelitis	30.2	IL6 IL10 CCR6
45	thyroiditis	30.2	IL6 IL2 IL10
46	autoimmune disease	30.2	IL6 IL2 IL10 CD274 CCR6
47	reticulosarcoma	30.2	PAX5 MYC CD68 BCL6
48	candidiasis	30.1	IL6 IL2 IL10 CCR6
49	rubella	30.1	IL6 IL2 IL10
50	crohn's disease	30.0	IL6 IL2 IL10 CCR6

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:

Sources

Symptoms & Phenotypes for Central Nervous System Lymphoma

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

²⁶ (show all 18)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased shRNA abundance (Z-score < -2)	GR00366-A-111	9.6	MGMT
2	Decreased shRNA abundance (Z-score < -2)	GR00366-A-12	9.6	CD274
3	Decreased shRNA abundance (Z-score < -2)	GR00366-A-120	9.6	CD274 PRDM1
4	Decreased shRNA abundance (Z-score < -2)	GR00366-A-149	9.6	PRDM1
5	Decreased shRNA abundance (Z-score < -2)	GR00366-A-152	9.6	PRDM1
6	Decreased shRNA abundance (Z-score < -2)	GR00366-A-160	9.6	CD274
7	Decreased shRNA abundance (Z-score < -2)	GR00366-A-171	9.6	PRDM1
8	Decreased shRNA abundance (Z-score < -2)	GR00366-A-179	9.6	PRDM1
9	Decreased shRNA abundance (Z-score < -2)	GR00366-A-191	9.6	CD274
10	Decreased shRNA abundance (Z-score < -2)	GR00366-A-212	9.6	CD274
11	Decreased shRNA abundance (Z-score < -2)	GR00366-A-213	9.6	CD274
12	Decreased shRNA abundance (Z-score < -2)	GR00366-A-30	9.6	PRDM1
13	Decreased shRNA abundance (Z-score < -2)	GR00366-A-32	9.6	CD274
14	Decreased shRNA abundance (Z-score < -2)	GR00366-A-37	9.6	MGMT
15	Decreased shRNA abundance (Z-score < -2)	GR00366-A-59	9.6	MGMT
16	Decreased shRNA abundance (Z-score < -2)	GR00366-A-60	9.6	PRDM1
17	Decreased shRNA abundance (Z-score < -2)	GR00366-A-72	9.6	MGMT
18	Decreased shRNA abundance (Z-score < -2)	GR00366-A-99	9.6	PRDM1

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.42	BCL6 CCR6 CD274 CD68 CDKN2A CXCL12
2	immune system	MP:0005387	10.39	BCL6 CCR6 CD274 CD68 CDKN2A CXCL12
3	cellular	MP:0005384	10.37	BCL6 CD274 CDKN2A CXCL12 CXCL13 CXCR5
4	cardiovascular system	MP:0005385	10.31	BCL6 CCR6 CDKN2A CXCL12 IL10 IL2
5	homeostasis/metabolism	MP:0005376	10.29	BCL6 CCR6 CD274 CDKN2A IL10 IL2
6	mortality/aging	MP:0010768	10.25	BCL6 CD274 CDKN2A CXCL12 IL10 IL2
7	endocrine/exocrine gland	MP:0005379	10.21	BCL6 CDKN2A IL10 IL2 IL6 MGMT
8	liver/biliary system	MP:0005370	10.13	BCL6 CDKN2A CXCL12 IL10 IL2 IL6
9	no phenotypic analysis	MP:0003012	10.03	BCL6 CD274 CD68 CDKN2A CXCL12 IL10
10	muscle	MP:0005369	10.02	BCL6 CDKN2A CXCL12 IL10 IL6 MYC
11	neoplasm	MP:0002006	10.02	CDKN2A IL10 IL2 IL6 MGMT MYC
12	normal	MP:0002873	9.81	BCL6 CCR6 CXCL12 CXCR5 IL10 MYC
13	reproductive system	MP:0005389	9.65	BCL6 CDKN2A CXCL12 IL10 IL2 IL6
14	respiratory system	MP:0005388	9.23	BCL6 CDKN2A IL10 IL2 IL6 MGMT

Sources

Drugs & Therapeutics for Central Nervous System Lymphoma

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Teniposide

Approved

Phase 4

29767-20-2

34698

Fotemustine

Investigational

Phase 4

92118-27-9

Formoterol Fumarate

Phase 4

Mechlorethamine

Approved, Investigational

Phase 3

51-75-2

4033

Cefepime

Approved, Investigational

Phase 3

88040-23-7

5479537

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Ketamine

Approved, Vet_approved

Phase 3

6740-88-1

3821

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Ondansetron

Approved

Phase 3

99614-02-5

4595

Dalteparin

Approved

Phase 3

9005-49-6

Tinzaparin

Approved

Phase 3

9041-08-1, 9005-49-6

25244225

Dextromethorphan

Approved

Phase 3

125-71-3

5360696 5362449

Caspofungin

Approved

Phase 3

162808-62-0, 179463-17-3

2826718 468682

Amphotericin B

Approved, Investigational

Phase 3

1397-89-3

5280965 14956

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Idarubicin

Approved

Phase 2, Phase 3

58957-92-9

42890

St. John's Wort

Approved, Investigational, Nutraceutical

Phase 3

84082-80-4

Pancreatic Polypeptide

Investigational

Phase 3

59763-91-6

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Anesthetics, Dissociative

Phase 3

Antifungal Agents

Phase 3

Analgesics

Phase 3

Cola

Phase 3

Neurotransmitter Agents

Phase 3

Liver Extracts

Phase 3

Analgesics, Opioid

Phase 3

Psychotropic Drugs

Phase 3

Anti-Anxiety Agents

Phase 3

Antipsychotic Agents

Phase 3

Fibrinolytic Agents

Phase 3

Anticoagulants

Phase 3

Heparin, Low-Molecular-Weight

Phase 3

Antiparasitic Agents

Phase 3

Antiprotozoal Agents

Phase 3

Excitatory Amino Acid Antagonists

Phase 3

Narcotics

Phase 3

Anesthetics

Phase 3

Anesthetics, General

Phase 3

Anesthetics, Intravenous

Phase 3

Amebicides

Phase 3

Liposomal amphotericin B

Phase 3

Serotonin

Investigational, Nutraceutical

Phase 3

50-67-9

5202

tannic acid

Approved

Phase 1, Phase 2

1401-55-4

Benzocaine

Approved, Investigational

Phase 1, Phase 2

94-09-7, 1994-09-7

2337

Mitoxantrone

Approved, Investigational

Phase 1, Phase 2

65271-80-9

4212

Nedaplatin

Approved, Investigational

Phase 2

95734-82-0

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Ganciclovir

Approved, Investigational

Phase 2

82410-32-0

3454

Interventional clinical trials:

(show top 50) (show all 191)

#	Name	Status	NCT ID	Phase	Drugs
1	The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.	Unknown status	NCT01960192	Phase 4	HD-MTX-Ara-C regimen;FVD regimen
2	Phase IV Study on the Role of Whole Brain Irradiation in Primary CNS Lymphoma (PCNSL) After High-dose Methotrexate	Completed	NCT00153530	Phase 4	methotrexate
3	Open Randomized Prospective Clinical Study of Rituximab Combined With Fotemustine, Pemetrexed, Dexamethasone Versus Rituximab Plus Methotrexate, Cytarabine, and Dexamethasone in the Treatment of Primary Central Nervous System Lymphoma	Recruiting	NCT04083066	Phase 4	rituximab in combination with methotrexate, cytarabine and dexamethasone
4	High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial	Unknown status	NCT02531841	Phase 3	Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
5	Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB	Unknown status	NCT00020865	Phase 3	cefepime hydrochloride;levofloxacin
6	A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients	Unknown status	NCT01316744	Phase 3	ketamine hydrochloride
7	A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters	Completed	NCT00006083	Phase 3	Fragmin
8	Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer	Completed	NCT00006348	Phase 3	ondansetron
9	A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients	Completed	NCT00003687	Phase 3	dextromethorphan hydrobromide;morphine sulfate
10	Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial	Completed	NCT00005805	Phase 3
11	Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT)	Completed	NCT00750009	Phase 3
12	A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia	Completed	NCT00008359	Phase 3	caspofungin acetate;liposomal amphotericin B
13	A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
14	Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy	Recruiting	NCT02657785	Phase 2, Phase 3	R-IDARAM plus intrathecal chemotherapy
15	Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With Primary CNS Lymphoma	Recruiting	NCT02836158	Phase 2, Phase 3	R-IDARAM plus intrathecal chemotherapy
16	Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Primary Central Nervous System Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation	Recruiting	NCT03733327	Phase 2, Phase 3	Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
17	Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line	Recruiting	NCT02313389	Phase 3	Rituximab, Methotrexate, Temozolomide
18	Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma	Unknown status	NCT02934204	Phase 2	methotrexate;temozolomide
19	Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly	Unknown status	NCT00503594	Phase 2	Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
20	Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy	Unknown status	NCT00003261	Phase 2	methotrexate;zidovudine
21	Plasma and Cerebrospinal Fluid (CSF) Pharmacokinetics of Bendamustine as a Component of Salvage Therapy for Primary Central Nervous System Lymphoma (PCNSL)	Unknown status	NCT03392714	Phase 2	R-B(O)AD
22	Ketogenic Diet Adjunctive to High Dose Methotrexate Chemotherapy for Primary Central Nervous System Lymphoma	Unknown status	NCT02983942	Phase 1, Phase 2
23	MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma	Unknown status	NCT02399189	Phase 2	R-MT followed by auto-HSCT
24	Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)	Unknown status	NCT02779101	Phase 2	pembrolizumab
25	Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma	Unknown status	NCT03536039	Phase 2	NGR-hTNF;Doxorubicin;Cyclophosphamide;Vincristine;Prednisone
26	Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma	Unknown status	NCT00942747	Phase 2	temsirolimus
27	High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma – a Phase II Study	Unknown status	NCT00455286	Phase 2	Methotrexate;Methylprednisolone;Temozolomide
28	Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy	Unknown status	NCT00989352	Phase 2	Methotrexate;Lomustine;Procarbazine;Rituximab
29	Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma	Unknown status	NCT00032149	Phase 1, Phase 2	cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
30	Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)	Unknown status	NCT01735747	Phase 2	nedaplatin;vincristine;Temozolomide
31	Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)	Unknown status	NCT02819479	Phase 2	25% Mannitol;Low-dose Intra-arterial Bevacizumab
32	A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma	Completed	NCT00006264	Phase 2	ganciclovir;zidovudine
33	A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma	Completed	NCT00193973	Phase 2	Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
34	Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)	Completed	NCT00003061	Phase 2	cytarabine;methotrexate
35	Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma	Completed	NCT00000801	Phase 2	Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
36	Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma	Completed	NCT00074191	Phase 2	cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
37	Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma	Completed	NCT00074178	Phase 2	cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
38	Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma	Completed	NCT01011920	Phase 2	Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
39	Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma	Completed	NCT02669511	Phase 2	PQR309
40	Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Completed	NCT00210314	Phase 2	high dose methotrexate;high dose cytarabine
41	A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)	Completed	NCT02301364	Phase 2	Buparlisib (BKM120)
42	Phase I Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients With Primary Central Nervous Lymphoma (PCNSL)	Completed	NCT00727831	Phase 1, Phase 2	glucarpidase;leucovorin calcium;methotrexate
43	A Phase II Study of Intensive Methotrexate and Cytarabine Followed by High Dose Beam Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Completed	NCT00003632	Phase 2	carmustine;cytarabine;etoposide;melphalan;methotrexate
44	AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy	Completed	NCT00267865	Phase 2	Methotrexate;Rituximab;Leucovorin
45	Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL)	Completed	NCT01956695	Phase 2	Lenalidomide;Rituximab
46	Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma	Completed	NCT00068250	Phase 1, Phase 2	rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
47	Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study	Completed	NCT01083342	Phase 2	MTX, MVD, VIA
48	Hydroxyurea Treatment of EBV-Associated Primary CNS Lymphoma in Children and Adults With AIDS	Completed	NCT00002940	Phase 2	hydroxyurea
49	A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma	Completed	NCT00045539	Phase 2	leucovorin calcium;methotrexate;thiotepa
50	A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas	Completed	NCT00542919	Phase 2	enzastaurin

Search NIH Clinical Center for Central Nervous System Lymphoma

Sources

Genetic Tests for Central Nervous System Lymphoma

Sources

Anatomical Context for Central Nervous System Lymphoma

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

¹⁹

Central Nervous System

MalaCards organs/tissues related to Central Nervous System Lymphoma:

⁴⁰

Brain, B Cells, T Cells, Liver, Bone, Bone Marrow, Endothelial

Sources

Publications for Central Nervous System Lymphoma

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 2643)

#	Title	Authors	PMID	Year
1	Eye involvement in primary central nervous system lymphoma. ⁶¹	Farrall AL...Smith JR	32057762	2020
2	The Challenges of Applying Radiation in Primary Central Nervous System Lymphoma. ⁶¹	Dabaja B...Tsang R	32531380	2020
3	Effectiveness of digital PCR for MYD88L265P detection in vitreous fluid for primary central nervous system lymphoma diagnosis. ⁶¹	Chen K...Guan M	32536998	2020
4	Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ⁶¹	Young PA...Timmerman J	32229199	2020
5	Conventional MR and DW imaging findings of cerebellar primary CNS lymphoma: comparison with high-grade glioma. ⁶¹	He YX...Gao Q	32561819	2020
6	High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma. ⁶¹	Mahajan A...Wun T	32573292	2020
7	Primary Central Nervous System Lymphoma With Diffuse Neurolymphomatosis Involving Multiple Cranial and Spinal Nerve Roots. ⁶¹	Singh SS...Goyal M	32332304	2020
8	Correction to: atypical radiological findings of primary central nervous system lymphoma. ⁶¹	Lin X...Yu WY	32211926	2020
9	Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. ⁶¹	Dietrich J...Batchelor TT	32520407	2020
10	Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. ⁶¹	Velasco R...GELTAMO and GENOSEN group	32524392	2020
11	Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors. ⁶¹	Shen N...Liu Y	32533646	2020
12	Visual hallucinations as psychiatric onset of a primary central nervous system lymphoma: a case report and a brief review of literature on neoplasm-correlated neuropsychiatric disorders. ⁶¹	Napolitano M...Manzo V	32524322	2020
13	Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells. ⁶¹	Takashima Y...Yamanaka R	32108030	2020
14	High-dose methotrexate in ICU patients: a retrospective study. ⁶¹	Valade S...Darmon M	32535662	2020
15	Tirabrutinib: First Approval. ⁶¹	Dhillon S	32382949	2020
16	Primary dural lymphomas: Clinical presentation, management, and outcome. ⁶¹	Karschnia P...Baehring JM	32176324	2020
17	Risk Factors for Early Mortality in Patients with Primary Central Nervous System Lymphoma: A Large-Cohort Retrospective Study. ⁶¹	Zhou X...Liu Y	32251807	2020
18	Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment. ⁶¹	Zhang Y...Zhou DB	32452898	2020
19	A diagnostic challenge of primary Central nervous system lymphoma: from the eyes to the brain. ⁶¹	Su M...Yu S	32449877	2020
20	Atypical radiological findings of primary central nervous system lymphoma. ⁶¹	Lin X...Yu WY	32077984	2020
21	Sex-Specific Differences in Primary CNS Lymphoma. ⁶¹	Roetzer T...Woehrer A	32560244	2020
22	On Point in Primary CNS Lymphoma. ⁶¹	Tsang M...Rubenstein JL	32510610	2020
23	Early Detection of Secondary Central Nervous System Lymphoma on PET/CT. ⁶¹	Appaduray SP...Yan SX	32149796	2020
24	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. ⁶¹	Lauer EM...Scherer F	32452526	2020
25	Cerebrospinal Fluid Flow Cytometry: Utility in Central Nervous System Lymphoma Diagnosis. ⁶¹	Au KLK...Hahn C	32228724	2020
26	Advances and challenges in the treatment of primary central nervous system lymphoma. ⁶¹	Yang H...You H	32420657	2020
27	Maculopathy Associated With Osmotic Blood- Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma. ⁶¹	Simonett JM...Lin P	32484895	2020
28	Letter to the Editor Regarding Effects of the COVID-19 Outbreak in Northern Italy: Perspectives from the Bergamo Neurosurgery Department, and the Role of Radiosurgery as a Minimally Invasive Procedure for Primary Central Nervous System Lymphoma in the Pandemic Outbreak. ⁶¹	Alvarez Pinzon AM...Alonso JR	32380338	2020
29	Current status and quality of radiomics studies in lymphoma: a systematic review. ⁶¹	Wang H...Tian R	32472274	2020
30	Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma. ⁶¹	Baek DW...Moon JH	32408414	2020
31	Determination of cerebrospinal fluid adenosine deaminase activity cut-off for the diagnosis of tuberculous meningitis in Hong Kong. ⁶¹	Chan TCH...Leung DCW	32423993	2020
32	GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. ⁶¹	Takashima Y...Yamanaka R	32439996	2020
33	Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma. ⁶¹	Beca JM...Kouroukis CT	31931647	2020
34	Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. ⁶¹	van der Meulen M...Dirven L	32371123	2020
35	Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. ⁶¹	Sasaki N...Nagane M	32469065	2020
36	Usefulness of carbon-11-labeled methionine positron-emission tomography for assessing the treatment response of primary central nervous system lymphoma. ⁶¹	Miyakita Y...Narita Y	32129443	2020
37	Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study. ⁶¹	Bertaux M...Kas A	32405997	2020
38	Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. ⁶¹	Hou K...Feng Y	32540781	2020
39	LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme. ⁶¹	Ge L...Yan H	32237064	2020
40	Central Nervous System Lymphoma: Approach to Diagnosis and Treatment. ⁶¹	Correia CE...Grommes C	32496457	2020
41	Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects. ⁶¹	Zhang X...Liu Y	32416683	2020
42	Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography. ⁶¹	Kim HO...Kim JH	32443328	2020
43	Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients. ⁶¹	Zhou X...Xiao J	32397978	2020
44	Cell-Block cytology in diagnosis of primary central nervous system lymphoma: A case report. ⁶¹	Huang K...Tong Y	32243381	2020
45	Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma. ⁶¹	Ouyang T...Hong T	32311566	2020
46	Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma. ⁶¹	Mika T...Schroers R	31399528	2020
47	A National Consensus Survey for Current Practice in Brain Tumor Management III: Brain Metastasis and Primary Central Nervous System Lymphoma. ⁶¹	Kim SK...KSNO Guideline Working Group	32390350	2020
48	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. ⁶¹	Patel MP...Peters KB	32140975	2020
49	Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands. ⁶¹	van der Meulen M...Dinmohamed AG	32241841	2020
50	Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma. ⁶¹	Pai MP...Wang SC	32090349	2020

Sources

Genes for Central Nervous System Lymphoma

Genes related to Central Nervous System Lymphoma (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	23.65	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
2	BCL6	BCL6 Transcription Repressor	Protein Coding	15.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	CXCL13	C-X-C Motif Chemokine Ligand 13	Protein Coding	13.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	13.19	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
5	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	13.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	IL10	Interleukin 10	Protein Coding	12.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CD274	CD274 Molecule	Protein Coding	12.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	CXCR5	C-X-C Motif Chemokine Receptor 5	Protein Coding	12.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	12.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	PAX5	Paired Box 5	Protein Coding	12.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	12.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	12.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	PRDM1	PR/SET Domain 1	Protein Coding	12.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	TP53	Tumor Protein P53	Protein Coding	12.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	MALT1	MALT1 Paracaspase	Protein Coding	12.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	IL2	Interleukin 2	Protein Coding	11.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	RNU2-1	RNA, U2 Small Nuclear 1	RNA Gene	11.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	IL6	Interleukin 6	Protein Coding	11.88	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	CD68	CD68 Molecule	Protein Coding	11.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	FOXP1	Forkhead Box P1	Protein Coding	11.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	MTR	5-Methyltetrahydrofolate-Homocysteine Methyltransferase	Protein Coding	11.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	11.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	11.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	CCL19	C-C Motif Chemokine Ligand 19	Protein Coding	11.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	11.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
26	TNFRSF13C	TNF Receptor Superfamily Member 13C	Protein Coding	11.43	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
27	TNF	Tumor Necrosis Factor	Protein Coding	11.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Central Nervous System Lymphoma

Cosmic variations for Central Nervous System Lymphoma:

⁹

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM105231581	MYD88	haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma	c.818T>C	p.L273P	3:38141150-38141150	0

Copy number variations for Central Nervous System Lymphoma from CNVD:

⁷

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	250739	9	21967751	21994490	Methylation deletion	CDKN2A	CNS lymphoma

Sources

Expression for Central Nervous System Lymphoma

Search GEO for disease gene expression data for Central Nervous System Lymphoma.

Sources

Pathways for Central Nervous System Lymphoma

Pathways related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 44)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.03	TP53 MYD88 MYC MALT1 IL6 IL2
2	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.79	TP53 MYC IL6 IL2 IL10 CXCR5
3	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.65	TP53 MYC IL6 IL2 IL10 CXCR5
4	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.34	TP53 MYD88 MYC IL6 IL2 IL10
5	PAK Pathway ⁶³ Show member pathways Antioxidant Action of Vitamin-C ⁶³ Epithelial Adherens Junctions ⁶³	13.27	IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
6	Akt Signaling ⁶³ Show member pathways p38 Signaling ⁶³ Tec Kinases Signaling ⁶³	13.26	TP53 MYD88 IL6 IL2 IL10 CXCR5
7	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Regulation of toll-like receptor signaling pathway ¹	13.03	TP53 MYD88 MYC IL6 IL2 IL10
8	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	12.91	TP53 MYD88 MYC IL6 CXCL12 CDKN2A
9	Pathways in cancer ³⁶	12.8	TP53 MYC IL6 IL2 CXCL12 CDKN2A
10	Measles ³⁶ Show member pathways Epstein-Barr virus infection ³⁶ Influenza A ³⁶	12.79	TP53 MYD88 MYC IL6 IL2
11	Allograft rejection ¹ ³⁶ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶³ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶³ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.78	IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
12	NF-KappaB Family Pathway ⁶³ Show member pathways NF-KappaB (p50-p65) Pathway ⁶³	12.67	MYD88 MALT1 IL6 IL2 CXCL12
13	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.55	TP53 MYC IL6 IL2 IL10
14	JAK-STAT signaling pathway ³⁶ Show member pathways B-Cell Development ⁶³ IL-7 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁴ Interleukin-19, 20, 22, 24 ⁶⁵ Jak/STAT Signaling Pathway ⁶⁴ Type III interferon signaling ¹	12.42	MYC IL6 IL2 IL10 CXCL12
15	T cell receptor signaling pathway ³⁶ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁶ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.42	MYD88 MALT1 IL6 IL2 IL10 CD274
16	Human T-cell leukemia virus 1 infection ³⁶	12.23	TP53 MYC IL6 IL2 CDKN2A
17	Tuberculosis ³⁶	12.21	MYD88 MALT1 IL6 IL10
18	Cellular senescence (KEGG) ³⁶	12.13	TP53 MYC IL6 CDKN2A
19	Transcriptional misregulation in cancer ³⁶	12.11	TP53 PAX5 MYC IL6 BCL6
20	Immune response IFN alpha/beta signaling pathway ²² Show member pathways Cytokine Network ⁶³ Interferon alpha/beta signaling ⁶⁵ Regulation of IFNA signaling ⁶⁵	12.01	TP53 MYC IL6 IL2 IL10 CXCL12
21	C-type lectin receptor signaling pathway ³⁶ Show member pathways Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁴	12	MYD88 MALT1 IL6 IL2 IL10
22	Yersinia infection ³⁶	11.97	MYD88 IL6 IL2 IL10
23	Spinal Cord Injury ¹	11.96	TP53 MYC IL6 IL2
24	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁴	11.94	IL6 IL2 IL10 CD68
25	DNA Damage Response (only ATM dependent) ¹	11.93	TP53 MYC CDKN2A BCL6
26	Glioblastoma Multiforme ⁶³	11.88	TP53 MYC MGMT CDKN2A
27	NF-kappaB Signaling ⁴	11.84	PRDM1 PAX5 MYD88 MALT1 IL2 IL10
28	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁴ Show member pathways Chemokine receptors bind chemokines ⁶⁵ Viral protein interaction with cytokine and cytokine receptor ³⁶	11.83	IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
29	LT-BetaR Pathway ⁶³ Show member pathways Apoptosis and survival Lymphotoxin-beta receptor signaling ²²	11.78	IL2 CXCL13 CXCL12
30	Glucocorticoid receptor regulatory network ¹	11.78	TP53 IL6 IL2
31	Pertussis ³⁶	11.74	MYD88 IL6 IL10
32	Dendritic Cells Developmental Lineage Pathway ⁶⁴	11.72	IL6 IL2 IL10
33	Regulation of TP53 Expression and Degradation ⁶⁵ Show member pathways Regulation of TP53 Degradation ⁶⁵ Regulation of TP53 Expression ⁶⁵	11.71	TP53 PRDM1 CDKN2A
34	Bladder cancer ³⁶ ¹	11.71	TP53 MYC CDKN2A
35	Innate Lymphoid Cells Differentiation ⁶⁴	11.68	IL2 IL10 CXCR5 CCR6
36	Interleukin-4 and 13 signaling ⁶⁵	11.61	TP53 MYC IL6 IL10 BCL6
37	Hepatitis C and Hepatocellular Carcinoma ¹	11.53	TP53 MYC IL6
38	Malaria ³⁶	11.52	MYD88 IL6 IL10
39	African trypanosomiasis ³⁶	11.36	MYD88 IL6 IL10
40	IL-10 Pathway ⁶³	11.33	MYC IL6 IL10
41	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.27	TP53 IL6 IL2 CDKN2A
42	Cytokines and Inflammatory Response ¹	11.19	IL6 IL2 IL10
43	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁵	11.04	TP53 MYC CDKN2A
44	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶³	11.03	TP53 MYC CDKN2A

Sources

GO Terms for Central Nervous System Lymphoma

Cellular components related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cell	GO:0005623	9.23	MYC IL6 IL2 CXCR5 CXCL13 CXCL12

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.14	TP53 PAX5 MYC IL6 IL2 IL10
2	cellular response to DNA damage stimulus	GO:0006974	10.02	TP53 MYC MGMT FOXP1 BCL6
3	negative regulation of cell proliferation	GO:0008285	10	TP53 IL6 IL10 CDKN2A BCL6
4	positive regulation of gene expression	GO:0010628	9.95	TP53 PRDM1 MYD88 MYC IL6 CDKN2A
5	regulation of gene expression	GO:0010468	9.92	PRDM1 MYD88 MYC IL10 FOXP1
6	regulation of cell proliferation	GO:0042127	9.91	TP53 PRDM1 MYD88 BCL6
7	immune response	GO:0006955	9.86	IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
8	chemotaxis	GO:0006935	9.84	CXCR5 CXCL13 CXCL12 CCR6
9	positive regulation of cytosolic calcium ion concentration	GO:0007204	9.81	IL2 CXCR5 CXCL13 CCR6
10	positive regulation of T cell proliferation	GO:0042102	9.75	IL6 IL2 CD274
11	humoral immune response	GO:0006959	9.73	PAX5 IL6 CCR6
12	cell chemotaxis	GO:0060326	9.73	CXCR5 CXCL13 CXCL12 CCR6
13	chemokine-mediated signaling pathway	GO:0070098	9.71	CXCR5 CXCL13 CXCL12 CCR6
14	cytokine-mediated signaling pathway	GO:0019221	9.7	TP53 MYD88 MYC IL6 IL2 IL10
15	positive regulation of smooth muscle cell proliferation	GO:0048661	9.67	MYD88 MYC IL6 FOXP1
16	leukocyte chemotaxis	GO:0030595	9.63	IL10 CXCR5 CXCL13
17	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.62	TP53 IL6
18	regulation of tumor necrosis factor production	GO:0032680	9.61	MYD88 FOXP1
19	negative regulation of apoptotic process	GO:0043066	9.61	TP53 MYD88 MYC MGMT MALT1 IL6
20	germinal center formation	GO:0002467	9.58	CXCL13 BCL6
21	response to peptidoglycan	GO:0032494	9.57	MYD88 IL6
22	type 2 immune response	GO:0042092	9.55	IL10 BCL6
23	negative regulation of B cell apoptotic process	GO:0002903	9.5	IL2 FOXP1 BCL6
24	regulation of chemokine (C-X-C motif) ligand 2 production	GO:2000341	9.49	MYD88 FOXP1
25	cellular response to lipopolysaccharide	GO:0071222	9.17	MYD88 MALT1 IL6 IL10 CXCL13 CD68

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.56	IL6 IL2 IL10 CXCL12
2	cytokine activity	GO:0005125	9.55	IL6 IL2 IL10 CXCL13 CXCL12
3	kinase activator activity	GO:0019209	9.32	MALT1 IL2
4	core promoter sequence-specific DNA binding	GO:0001046	9.13	TP53 MYC FOXP1
5	protein self-association	GO:0043621	8.92	TP53 MYD88 MALT1 FOXP1

Sources

Sources for Central Nervous System Lymphoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia